Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPERAR trial of darolutamide with or without goserelin for metastatic extramammary Paget's disease
jRCT2031240219Phase 2Active, not recruiting
- Start
- Sep 2024
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of darolutamide and goserelin in extramammary Paget disease (EMPD) (2 cohorts). Primary endpoint: Response rate by central review. Started Sep 2024; status: active, not recruiting.
02
Drugs
darolutamidegoserelin
03
Conditions
extramammary Paget disease (EMPD)
Beyond the preview
Go deeper on jRCT2031240219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240219.